Adult neural stem cell therapy - Microbot Medical

Drug Profile

Adult neural stem cell therapy - Microbot Medical

Alternative Names: hCNS-SC; HuCNS-SC; HuCNS-SC cells; Neurodegenerative disorders stem cell therapy - Microbot Medical

Latest Information Update: 13 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator StemCells
  • Developer Microbot Medical; Oregon Health & Science University; StemCells; University of California at Irvine
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Myelin protein stimulants; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Retinal disorders

Highest Development Phases

  • Phase II Spinal cord injuries
  • Phase I Pelizaeus-Merzbacher disease
  • Preclinical Stroke
  • Suspended Alzheimer's disease; Dry age-related macular degeneration
  • Discontinued Neuronal ceroid lipofuscinosis

Most Recent Events

  • 28 Nov 2016 StemCells has been acquired and merged into Microbot Medical
  • 31 May 2016 StemCells terminates a long-term follow-up study for Dry age-related macular degeneration in USA due to a business decision (NCT02137915)
  • 31 May 2016 StemCells terminates a phase II Pathway trial in Spinal cord injuries in USA and Canada due to positive results which were not consistent over the time (NCT02163876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top